Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Gross Profit: 2013-2025

Historic Gross Profit for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $11.9 million.

  • Fortress Biotech's Gross Profit rose 16.91% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.1 million, marking a year-over-year decrease of 4.34%. This contributed to the annual value of $36.8 million for FY2024, which is 40.29% down from last year.
  • As of Q3 2025, Fortress Biotech's Gross Profit stood at $11.9 million, which was up 3.50% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Gross Profit registered a high of $28.3 million during Q3 2023, and its lowest value of $6.0 million during Q1 2023.
  • Its 3-year average for Gross Profit is $11.8 million, with a median of $10.2 million in 2024.
  • Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 204.32% in 2023, then plummeted by 64.14% in 2024.
  • Quarterly analysis of 5 years shows Fortress Biotech's Gross Profit stood at $8.8 million in 2021, then decreased by 0.74% to $8.7 million in 2022, then skyrocketed by 103.75% to $17.7 million in 2023, then slumped by 41.01% to $10.4 million in 2024, then rose by 16.91% to $11.9 million in 2025.
  • Its Gross Profit was $11.9 million in Q3 2025, compared to $11.5 million in Q2 2025 and $8.3 million in Q1 2025.